IsaacTafurMD

Oncology • Lubbock, TX

Physician

Join to view full profile

Are you Dr. Tafur?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
4101 22nd Pl
Lubbock, TX 79410
Phone+1 806-725-8000

Summary

Dr. Isaac Tafur, MD is an oncologist in Lubbock, Texas. He is currently licensed to practice medicine in Texas, New Mexico, and Indiana. He is affiliated with Covenant Hospital-Levelland and Nor-Lea Hospital District.

Education & Training

Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Hematology and Medical Oncology, 1998 - 2000
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Internal Medicine, 1996 - 1998
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1995 - 1996
National University of San MarcosClass of 1989

Certifications & Licensure

NM State Medical License 2005 - 2027
IN State Medical License 1998 - 2025
TX State Medical License 1999 - 2025

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Start of enrollment: 2012 Feb 01
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Molecular Genetics Studies of Cancer Patients and Their Relatives Start of enrollment: 1997 Apr 18
Recruiting
Join now to see all

Publications & Presentations

PubMed

13 citations
Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland: a potential for a diagnostic pitfall.
Ludvik R. Donner, Frank E. Mott, Isaac Tafur
Archives of Pathology & Laboratory Medicine. 2001-08-01